Is MYGN a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

657 people get MYGN articles and Market Currents by email alert.

Get email alerts on MYGN »

HEADLINES:

6 Ways You Can Profit From Molecular Diagnostics
Cory Renauer • Wed, May 22 • 11 Comments
Myriad Genetics: Disruptive Products For Cancer Diagnostics
David Zanoni • Sun, May 19 • 2 Comments
Genomic Health's New Prostate Test May Extend The Stock's Upward Climb
Amy Baldwin • Wed, May 15
Myriad Genetics: Strong Results Ahead Of Supreme Court Decision
PSalerno • Wed, May 15 • 12 Comments
Wall Street Breakfast: Must-Know News
Wall Street Breakfast • Wed, May 15 • 104 Comments
Myriad Genetics to Present at the Bank of America Merrill Lynch Health Care Conference

GlobeNewswire (May 14, 2013)
Sony Options Active As Shares Hit Fresh 52-Week High
Interactive Brokers • Mon, May 13
Position Yourself For Big Returns In The Stem Cell Space: Jason Kolbert
Life Sciences Report • Mon, May 13 • 4 Comments
Myriad Genetics' CEO Hosts Annual Day (Transcript)
Sat, May 11
Companies Fighting Against Prostate Cancer
Equity Options Guru • Thu, May 9 • 10 Comments
Myriad Genetics Management Discusses Q3 2013 Results - Earnings Call Transcript
Tue, May 7
Myriad Genetics Reports Third Quarter Fiscal Year 2013 Results

GlobeNewswire (May 7, 2013)
Atossa Genetics' Portfolio Can Detect Breast Cancer, But Can These Products Eradicate It?
OneMedPlace • Fri, May 3 • 2 Comments
Myriad Genetics Announces 2013 Analyst and Investor Day

GlobeNewswire (May 2, 2013)
Myriad to Present New Molecular Data for Patients With Prostate Cancer at the American Urological Association 2013 Annual Meeting

GlobeNewswire (May 2, 2013)
Myriad Genetics: Growth Stock, Hot Sector, Solid Industry
PSalerno • Mon, Apr 22
Myriad Genetics to Announce Third Fiscal Quarter 2013 Results on Tuesday, May 7, 2013

GlobeNewswire (Apr 18, 2013)
Myriad Adopts RainDance's Thunderstorm Platform for Next-Generation Sequencing Based Hereditary Cancer Panel

GlobeNewswire (Apr 17, 2013)
Wall Street Breakfast: Must-Know News
Wall Street Breakfast • Mon, Apr 15 • 49 Comments
Tuesday Options Brief: UNH, MYGN & OMPI
Interactive Brokers • Tue, Apr 2

To learn more about Seeking Alpha Pro, click here.

Myriad Genetics: Disruptive Products For Cancer Diagnostics
David Zanoni • Sun, May 19 • 2 Comments
Myriad Genetics: Strong Results Ahead Of Supreme Court Decision
PSalerno • Wed, May 15 • 12 Comments
Myriad Genetics: Growth Stock, Hot Sector, Solid Industry
PSalerno • Mon, Apr 22
Aggressive Growth: Myriad Genetics
Zacks Investment Research • Wed, Dec 19, 2012 • 1 Comment
Myriad's Revenue Growth Has Stabilized
Zacks Investment Research • Wed, May 18, 2011
Myriad: 2Q EPS In-Line, Beats on Revenues
Zacks Investment Research • Fri, Jan 28, 2011 • 2 Comments
Myriad Genetics: Growing Medical Diagnostics Franchise at Value Price
SeekingValue • Wed, Jun 30, 2010
Myriad Gene Patents Ruling Unsettles U.S. Biotech Industry
The Burrill Report • Mon, Apr 5, 2010 • 2 Comments
Closing Myriad Genetics After Oppenheimer Analyst Brings Out the Hammer
TraderMark • Tue, Jan 12, 2010
Myriad Genetics: Starting to Outperform
optionMONSTER • Wed, Dec 30, 2009
Restarting Myriad Genetics
TraderMark • Thu, Dec 24, 2009
Myriad's Not Doing Much
TraderMark • Fri, Nov 6, 2009 • 1 Comment
Myriad Genetics: Horrendous Chart but Still Interesting
TraderMark • Sun, Sep 27, 2009 • 3 Comments
Myriad Genetics' Home Run Earnings Report
TraderMark • Thu, Aug 27, 2009 • 1 Comment
How Far Myriad Has Fallen: Is Information Leaking out?
TraderMark • Thu, Jul 2, 2009 • 3 Comments
Myriad Genetics Spinoff Now in Place
John Clark • Wed, Jun 17, 2009 • 1 Comment
Gene Patenting Will Hinder Biotechs and Drugmakers from Curing Maladies
Everyday Finance • Thu, May 14, 2009
Why I'm Exiting Myriad Genetics
TraderMark • Tue, May 5, 2009
Rethinking Myriad After 'Those in the Know' Have Left
TraderMark • Mon, May 4, 2009 • 1 Comment
Impact of Blowout Earnings in a Downward Trending Market
Dr. Kris • Thu, Mar 26, 2009 • 4 Comments

6 Ways You Can Profit From Molecular Diagnostics
Cory Renauer • Wed, May 22 • 11 Comments
Genomic Health's New Prostate Test May Extend The Stock's Upward Climb
Amy Baldwin • Wed, May 15
Wall Street Breakfast: Must-Know News
Wall Street Breakfast • Wed, May 15 • 104 Comments
Sony Options Active As Shares Hit Fresh 52-Week High
Interactive Brokers • Mon, May 13
Position Yourself For Big Returns In The Stem Cell Space: Jason Kolbert
Life Sciences Report • Mon, May 13 • 4 Comments
Companies Fighting Against Prostate Cancer
Equity Options Guru • Thu, May 9 • 10 Comments
Atossa Genetics' Portfolio Can Detect Breast Cancer, But Can These Products Eradicate It?
OneMedPlace • Fri, May 3 • 2 Comments
Wall Street Breakfast: Must-Know News
Wall Street Breakfast • Mon, Apr 15 • 49 Comments
Tuesday Options Brief: UNH, MYGN & OMPI
Interactive Brokers • Tue, Apr 2
Response Genetics' Competitors: Who To Watch, Who To Worry About
Bay Area Biotech • Fri, Feb 8 • 7 Comments
Can Amgen Unlock DeCODE's Value?
Stephen Simpson • Mon, Dec 10, 2012 • 1 Comment
Testing, Testing: Analyst Kevin DeGeeter On 5 Good Bets In Cancer Diagnostics
Life Sciences Report • Fri, Nov 30, 2012 • 1 Comment
Qiagen: Downside Priced In, CDx And Automation Upside, Undervalued Compared To Peers
Dave Westenberg • Sat, Sep 29, 2012
6 Low-Debt Mid Caps With Plenty Of Cash
ZetaKap • Mon, Sep 24, 2012 • 2 Comments
Questcor Poised To Rally To $80 On Continued Sales Growth
LifeSci Advisors • Thu, Sep 6, 2012 • 14 Comments
7 Low-Debt Mid-Cap Stocks Flush With Cash Reserves
ZetaKap • Thu, Aug 23, 2012
Wall Street Breakfast: Must-Know News
Wall Street Breakfast • Fri, Aug 17, 2012 • 30 Comments
Cepheid: Awesome Company, But Overpriced
Dave Westenberg • Fri, Aug 10, 2012
Coming Wave Of Companion Diagnostics: Who's Making A Splash
Dave Westenberg • Thu, Jul 26, 2012 • 7 Comments
Wall Street Breakfast: Must-Know News
Wall Street Breakfast • Fri, Jul 20, 2012 • 31 Comments

Myriad Genetics' CEO Hosts Annual Day (Transcript)
Sat, May 11
Myriad Genetics Management Discusses Q3 2013 Results - Earnings Call Transcript
Tue, May 7
Myriad Genetics' CEO Discusses F2Q13 Results - Earnings Call Transcript
Tue, Feb 5
Myriad Genetics' CEO Discusses F1Q13 Results - Earnings Call Transcript
Mon, Nov 5, 2012
Myriad Genetics' CEO Discusses F4Q12 Results - Earnings Call Transcript
Tue, Aug 14, 2012
Myriad Genetics' CEO Presents at Bank of America Merrill Lynch Health Care Conference (Transcript)
Fri, May 18, 2012
Myriad Genetics' CEO Discusses Q1 2012 Results - Earnings Call Transcript
Tue, May 1, 2012
Myriad Genetics' CEO Discusses F2Q12 Results - Earnings Call Transcript
Tue, Jan 31, 2012
Myriad Genetics' CEO Presents at 30th Annual J.P. Morgan Healthcare Conference (Transcript)
Wed, Jan 11, 2012
Myriad Genetics' Management Presents at 22nd Annual Oppenheimer Healthcare Conference - Conference Call Transcript
Wed, Dec 14, 2011
Myriad Genetics' CEO Discusses F1Q12 Results - Earnings Call Transcript
Tue, Nov 1, 2011
Myriad Genetics' CEO Discusses Q4 2011 Results - Earnings Call Transcript
Tue, Aug 9, 2011 • 1 Comment
Myriad Genetics Inc. F2Q10 Earnings Conference Call
Tue, Feb 2, 2010 • 1 Comment
Myriad Genetics, Inc F4Q09 (Qtr End 06/30/09) Earnings Call Transcript
Tue, Aug 25, 2009
Myriad Genetics F3Q09 (Qtr End 03/31/09) Earnings Call Transcript
Wed, May 6, 2009
Myriad Genetics Inc. F2Q09 (Qtr End 12/31/08) Earnings Call Transcript
Tue, Feb 3, 2009
Myriad Genetics, Inc. F1Q09 (Qtr. End 09/30/08) Earnings Call Transcript
Tue, Nov 4, 2008
Myriad Genetics, Inc. F4Q08 (Qtr End 06/30/08) Earnings Call Transcript
Tue, Aug 19, 2008 • 1 Comment
Myriad Genetics, Inc. F3Q08 (Qtr. End 03/31/08) Earnings Call Transcript
Tue, May 6, 2008
Myriad Genetics, Inc. F2Q08 (Qtr. End 12/31/07) Earnings Call Transcript
Wed, Feb 6, 2008

The Technical Indicator: Charting a persistent May uptrend

at MarketWatch.com (Tue, 12:07PM)
Angelina Jolie star power extends to stock

at MarketWatch.com (May 14, 2013)
Jolie's Decision Boosts BRCA Test-Maker Myriad

at CNBC.com (May 14, 2013)
Myriad Genetics to Present at the Bank of America Merrill Lynch Health Care Conference

GlobeNewswire (May 14, 2013)
Myriad Genetics Reports Third Quarter Fiscal Year 2013 Results

GlobeNewswire (May 7, 2013)
Myriad Genetics Announces 2013 Analyst and Investor Day

GlobeNewswire (May 2, 2013)
Myriad to Present New Molecular Data for Patients With Prostate Cancer at the American Urological Association 2013 Annual Meeting

GlobeNewswire (May 2, 2013)
Myriad Genetics to Announce Third Fiscal Quarter 2013 Results on Tuesday, May 7, 2013

GlobeNewswire (Apr 18, 2013)
Myriad Adopts RainDance's Thunderstorm Platform for Next-Generation Sequencing Based Hereditary Cancer Panel

GlobeNewswire (Apr 17, 2013)
Ben Weiss's Eye on Asia: Genomics companies ripe for flurry of mergers

at MarketWatch.com (Apr 16, 2013)
The Technical Indicator: Charting the market crosscurrents

at MarketWatch.com (Apr 16, 2013)
Myriad and PharmaMar Announce First Commercial Partnership With Myriad's New HRD Test

GlobeNewswire (Mar 26, 2013)
BRCA Testing Granted Preventive Care Designation Under the Affordable Care Act

GlobeNewswire (Mar 6, 2013)
Myriad's Prolaris(R) Test Predicts Risk of Prostate Cancer Recurrence in Fourth Peer Reviewed Study

GlobeNewswire (Mar 5, 2013)
Noridian Prices Molecular Pathology Codes; Myriad Confirms Guidance for Fiscal 2013

GlobeNewswire (Mar 1, 2013)
Myriad Genetics Reports Second Quarter Fiscal Year 2013 Results

GlobeNewswire (Feb 5, 2013)
Myriad Genetics to Announce Second Fiscal Quarter 2013 Results on Tuesday, February 5, 2013

GlobeNewswire (Jan 15, 2013)
Midday Movers: F, RIG & More

at CNBC.com (Jan 3, 2013)
Myriad Genetics to Present at the 2013 J.P. Morgan Annual Healthcare Conference

GlobeNewswire (Dec 17, 2012)
After-Hours Buzz: LTD, GILD & More

at CNBC.com (Dec 10, 2012)

MYGN vs. ETF Alternatives

Company Description

Myriad Genetics, Inc. is a leading healthcare company focused on the development and marketing of novel molecular diagnostic products. We believe that the future of medicine lies in a shift from a treatment paradigm to a prevention paradigm. By understanding the genetic basis of disease, we... More

Sector: Services

Industry: Research Services

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, May 15, 3:22 PM Gene-related stocks are getting a big bump today on the back of Angelina Jolie's recent decision to have a mastectomy to prevent possible breast cancer: Rosetta Genomics (ROSG +15.5%), Genetic Technologies (GENE +12.9%), Diagnocure (DGCRF.PK +12%), GeneNews (GNSWF.PK +5%). Myriad Genetics (MYGN -2.2%) is lower on a bout of profit-taking, possibly exacerbated by news of some insider selling today by its CEO as well. Comment! [Healthcare, On the Move]
Tuesday, May 14, 6:59 PM Myriad Genetics (MYGN +3%) finished the day solidly higher on the back of a New York Times op-ed piece by Angelina Jolie outlining her decision to have a double mastectomy after learning she had an 87% chance of developing breast cancer. MYGN holds the patent on the test that made the determination, as well as the genes themselves. The test looks for defects in the BRCA1 or BRCA2 genes, which are the cause of most hereditary breast cancer cases. Comment! [Healthcare, On the Move]
Tuesday, May 7, 4:45 PM More on Myriad Genetics (MYGN): FQ3 beats across the board on a 12% Y/Y increase in revenue. Molecular diagnostic testing revenue rose +20% over the prior year, while revenue from its BRACAnalysis test, which represented 74% of total revenue, grew by 9%. Operating income +26%, while operating margin rose to 37% from 35.5%. Shares +2.5% AH. Comment! [Healthcare, Earnings, On the Move]
Tuesday, May 7, 4:27 PM Myriad Genetics (MYGN): Q1 EPS of $0.46 beats by $0.07. Revenue of $156.5M (+21% Y/Y) beats by $8.25M. (PR) Comment! [Earnings, Breaking News]
Tuesday, May 7, 12:10 AM Notable earnings after Tuesday’s close: ANDE, ARAY, AWK, AXLL, BIO, BIOL, BMC, BWC, CA, CDXS, CHRW, CODI, DGI, DGIT, DIS, DVA, EA, ENPH, EXEL, GA, GPOR, HTA, IAG, JAZZ, KGC, LYV, MAKO, MCEP, MCK, MDLZ, MITK, MRO, MYGN, NVTL, OAS, OCLR, OHI, ONXX, ORA, PRI, RBCN, SD, SGEN, SYMC, SYNC, TRIP, TWO, URS, VCLK, WBMD, WFM, WMB, WPZ, WTI, Z 1 Comment [Earnings]
Monday, May 6, 5:35 PM Notable earnings after Tuesday’s close: ANDE, ARAY, AWK, AXLL, BIO, BIOL, BMC, BWC, CA, CDXS, CHRW, CODI, DGI, DGIT, DIS, DVA, EA, ENPH, EXEL, GTEK, GA, GPOR, IAG, JAZZ, KGC, LYV, MAKO, MCEP, MCK, MDLZ, MITK, MRO, MYGN, NVTL, OAS, OCLR, OHI, ONXX, ORA, PRI, RBCN, SD, SGEN, SYMC, SYNC, TRIP, TWO, URS, VCLK, WBMD, WFM, WMB, WPZ, WTI, Z 1 Comment [Earnings]
Monday, April 15, 12:38 PM Heard in the Myriad Genetics (MYGN +5.5%) Supreme Court case: Justice Scalia asks why a company would incur huge development costs if it is prohibited from patenting discoveries; Sotomayor, Breyer, and Kennedy ask if middle ground is possible wherein patents are allowed on cDNA but not an "isolated DNA"; Myriad's lawyers asked to consider if middle ground would grant "sufficient protection for innovation and research." (Bloomberg) Comment! [Healthcare, On the Move]
Monday, April 15, 11:37 AM Myriad Genetics (MYGN +2.7%) spikes into positive territory after Reuters says U.S. Supreme Court Justices "indicate a reluctance to issue [a] broad ruling" regarding contentious gene patenting. (Earlier: Court to hear arguments in gene patent case) Comment! [Healthcare, On the Move]
Monday, April 15, 5:53 AM The Supreme Court is due to hear arguments today on whether it's possible to patent isolated human genes in a debate that encompasses the concept that IP can't cover "laws of nature." The case involves Myriad Genetics (MYGN), which holds two patents that allow it to genetically screen those at risk of breast or ovarian cancer. The impact of any ruling on the human-gene field will probably be limited, although it could have ramifications for the wider pharmaceuticals sector, agriculture, industrial microbiology and alternative fuels. 1 Comment [Healthcare, Top Stories]
Monday, March 4, 1:38 PM Myriad Genetics (MYGN -2.3%) slips today, despite reaffirming its FY13 outlook. The company says it's anticipating its EPS at the higher end of its guidance range of $1.55 - $1.58, in line with the Street consensus of $1.58. It also maintains FY13 revenue at the higher end of its $575M - $585M range as well. Analysts are looking for $583.3M. However, Oppenheimimer cut its price target on the shares after Noridian, the Medicare contractor for Utah, reduced Integrated BRACAnalysis pricing by 16.3%. MYGN gets 10% of its revenue from Medicare. Comment! [Healthcare, On the Move, Earnings]
Tuesday, February 5, 6:09 PM More on Myriad Genetics (MYGN): FQ2 easily beats Street estimates on a 21% Y/Y jump in total sales. Molecular diagnostic testing revenue +20%, Oncology +16%, and Women's Health +27% over the prior year period. The company raises FY13 guidance, now expecting to earn between $1.55 - $1.58 per share on revenue of around $575M to $585M. Street estimates are for an EPS of $1.54 on revenue of $580M. Shares +1.3% AH. Comment! [Healthcare, Earnings, On the Move]
Tuesday, February 5, 4:25 PM Myriad Genetics (MYGN): FQ2 EPS of $0.42 beats by $0.04. Revenue of $149.1M (+21% Y/Y) beats by $5.39M. Shares +2.4% AH. (PR) Comment! [Earnings, Breaking News, Healthcare]
Tuesday, February 5, 12:10 AM Notable earnings after Tuesday’s close: AFL, BNNY, BV, CBL, CERN, CHRW, CME, CMG, DIS, ENTR, EQR, EXPE, FISV, GLUU, GNW, GTAT, HAIN, HRZN, INFN, JIVE, KFN, KIM, LNC, MWA, MYGN, NLY, NSR, PACB, PNRA, SFLY, SIMG, SU, THOR, TRMB, TTWO, UNM, USNA, ZNGA 1 Comment [Earnings]
Monday, February 4, 5:35 PM Notable earnings after Tuesday’s close: AFL, BNNY, BV, CBL, CERN, CHRW, CME, CMG, DIS, ENTR, EQR, EXPE, FISV, GLUU, GNW, GTAT, HAIN, HRZN, INFN, JIVE, KFN, KIM, LNC, MWA, MYGN, NLY, NSR, PACB, PNRA, SFLY, SIMG, SU, THOR, TRMB, TTWO, UNM, USNA, ZNGA Comment! [Earnings]
Monday, December 31, 2012, 9:00 AM Not all diagnostics companies are worried at the prospect of the Supreme Court striking down patents on two cancer-related genes "owned" by Myriad (MYGN) in a decision that is due to come in 2013. Quest (DGX) says it could be a "positive development," as it would "open new opportunities to develop new testing services." Myriad, which has spent 17 years and $500M on isolating the "DNA molecules and processes," isn't so sanguine. Comment! [Healthcare]
Monday, December 10, 2012, 4:23 PM Myriad Genetics (MYGN) enters into a research collaboration with Sanofi (SNY) and Population Health Research Institute at Hamilton Health Sciences and McMaster University to perform protein biomarker research for the Outcome Reduction with Initial Glargine Intervention, or ORIGIN, study. The study is the world's longest and largest randomized clinical trial in pre/early-stage diabetes. The collaboration could represent up to $10M in revenue for MYGN over the next two fiscal years, and is factored into FY13 revised guidance. Comment! [Healthcare]

Capitalist Bull
Today's Strong Breakouts & Follow Throughs: $EQIX $LRCX $WFC $MYGN $FOR $QIHU $TSM $GOOG $CPA http://stks.co/tBlN
May 8, 1:53 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ltfinger
New Upgrades (4/12/13): $MGIC, $MN, $MYGN, $NMM, $NSC, $NVDA, $SCVL, $TRIP, $TZOO, $VAR, $VRTX, $WCRX, $WEN, $WYN
Apr 15, 9:01 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ltfinger
Today's Potential Upgrades (3/13/13): $AVB, $CHRW, $CPRT, $DO, $DRC, $MYGN, $VRA, $WFM, $ZUMZ
Mar 13, 10:46 PM
Reply (3)

• !Report Abuse
View all 3 replies
ltfinger: There is still hope, but $VRA is technical within a downtrend with 13 MAR's price activity hitting neutral territory..
Mar 14, 3:23 PM
• !Report Abuse
ltfinger: $DKS is also in the same boat but fully extended in the downtrend with resistance at 48.20...
Mar 14, 3:25 PM
• !Report Abuse
Add a reply...

140 characters

MagicDiligence
Myriad Genetics $MYGN back in MFI after decline yesterday following downgrade. Still growing strong, looks like a good buy opportunity.
Jan 4, 8:44 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Bryant
Sherwin-Williams (SHW), Ultimate Software (ULTI), Team (TISI), V.F. Corporation (VFC), & Myriad Genetics (MYGN) rose Monday on unusual vol.
11/12/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
6 Low-Debt Mid Caps With Plenty Of Cash http://bit.ly/OQdZWP $GNTX $LANC $MKTAY.PK $MSM $MYGN $THOR @ZetaKap
9/24/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

The Wall Street Transcript
A Focus on ROIC in Small and Micro-Cap Investing; MM Discusses $GE, $JNJ, $MMM, $FCS, $IRF, $MYGN, $PAAS - http://su.pr/1eO71j
9/14/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
7 Low-Debt Mid-Cap Stocks Flush With Cash Reserves http://bit.ly/Pe3LKQ $MKTAY.PK $CIE $MYGN $GNTX $PAAS $MSM $SGEN @ZetaKap
8/23/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

MagicDiligence
Weekly roundup of stocks moving in and out of Magic Formula Investing $TRW $FRX $MYGN and many others http://bit.ly/R9WJdy
8/19/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
5 Small Cap Services Stocks With Plenty Of Cash On Hand http://bit.ly/KC8m6c $BKE $EZPW $ITRN $MIND $MYGN @ZetaKap
6/12/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

ltfinger
Today's Potential Upgrades (3/13/13): $AVB, $CHRW, $CPRT, $DO, $DRC, $MYGN, $VRA, $WFM, $ZUMZ
Mar 13, 10:46 PM
Reply (3)

• !Report Abuse
View all 3 replies
ltfinger: There is still hope, but $VRA is technical within a downtrend with 13 MAR's price activity hitting neutral territory..
Mar 14, 3:23 PM
• !Report Abuse
ltfinger: $DKS is also in the same boat but fully extended in the downtrend with resistance at 48.20...
Mar 14, 3:25 PM
• !Report Abuse
Add a reply...

140 characters

MYGN Myriad Genetics, Inc.

MYGN

Myriad Genetics, Inc.